Qualigen Therapeutics (FRA:7R90) Treasury Stock : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Qualigen Therapeutics's treasury stock for the quarter that ended in Sep. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Qualigen Therapeutics Treasury Stock Historical Data

The historical data trend for Qualigen Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Treasury Stock Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Treasury Stock

Qualigen Therapeutics Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Qualigen Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Qualigen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

QLGN:USA 7R90:Germany

Address

5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008

Website

https://www.qlgntx.com

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines